Expression of RBMS3 in Breast Cancer Progression.
RNA-binding protein 3 (RBMS3)
cancer prevention
carcinogenesis
epithelial–mesenchymal transition (EMT)
target discovery
target therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
15
12
2022
revised:
25
01
2023
accepted:
30
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stranded-interacting protein 3 (RBMS3) expression in clinical material using immunohistochemical (IHC) reactions in cases of ductal breast cancer (in vivo), and to determine the level of RBMS3 expression at both the protein and mRNA levels in breast cancer cell lines (in vitro). Moreover, the data obtained in the in vivo and in vitro studies were correlated with the clinicopathological profiles of the patients. Material for the IHC studies comprised 490 invasive ductal carcinoma (IDC) cases and 26 mastopathy tissues. Western blot and RT-qPCR were performed on four breast cancer cell lines (MCF-7, BT-474, SK-BR-3 and MDA-MB-231) and the HME1-hTERT (Me16C) normal immortalized breast epithelial cell line (control). The Kaplan-Meier plotter tool was employed to analyze the predictive value of overall survival of
Identifiants
pubmed: 36769184
pii: ijms24032866
doi: 10.3390/ijms24032866
pmc: PMC9917836
pii:
doi:
Substances chimiques
RNA, Messenger
0
RBMS3 protein, human
0
Trans-Activators
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Adv Anat Pathol. 2020 Jan;27(1):27-35
pubmed: 31045583
J Mol Biol. 2007 Aug 17;371(3):585-95
pubmed: 17586524
Med Oncol. 2015 Feb;32(2):459
pubmed: 25588924
Cancer Res. 2011 Oct 1;71(19):6106-15
pubmed: 21844183
Anticancer Res. 2015 Jul;35(7):3961-8
pubmed: 26124343
Genes Cells. 2000 Feb;5(2):127-41
pubmed: 10672043
Oncol Rep. 2020 Jul;44(1):55-68
pubmed: 32627033
Adv Exp Med Biol. 2018;1060:99-114
pubmed: 30155624
Am J Cancer Res. 2016 Nov 01;6(11):2679-2689
pubmed: 27904780
Oncol Res. 2018 Jan 19;26(1):9-15
pubmed: 28409548
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109
pubmed: 34527184
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Oncotarget. 2016 Sep 27;7(39):64148-64167
pubmed: 27580177
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Chem Biol Interact. 2023 Jan 5;369:110260
pubmed: 36414028
Int J Mol Sci. 2022 Sep 17;23(18):
pubmed: 36142783
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211004921
pubmed: 33910421
J Exp Clin Cancer Res. 2019 Feb 28;38(1):105
pubmed: 30819235
Mol Oncol. 2010 Jun;4(3):192-208
pubmed: 20452298
Oncogene. 2021 Nov;40(46):6430-6442
pubmed: 34608266
Breast Cancer. 2022 May;29(3):541-561
pubmed: 35020130
Genomics. 2021 Jul;113(4):1689-1704
pubmed: 33845141
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
DNA Cell Biol. 2012 Jul;31(7):1245-51
pubmed: 22372950
Oncol Rep. 2016 Nov;36(5):2745-2754
pubmed: 27633896
Virchows Arch. 2014 Jul;465(1):1-14
pubmed: 24878755
Clin Cancer Res. 2019 Feb 1;25(3):1022-1035
pubmed: 30279231
Gene. 2000 Feb 8;243(1-2):27-36
pubmed: 10675610